Program
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312
Its studies are mostly in Lupus Erythematosus, Systemic · Lymphoma, Non-Hodgkin, led by CytoCares.
Drug pageAnti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 1, since Aug 28, 20234 company-led studies, 4 open or runningNext primary completion: Sep 10, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CytoCares | 44 open or running | phase 1since Aug 28, 2023 | Aug 28, 2023 | Sep 10, 2027phase 1 · NCT07177911 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 28, 2023First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT06037018 · 44 planned · China
- Jan 20, 2025Early phase 1 study in Lupus Erythematosus, SystemicNCT06888960 · 18 planned · China
- Sep 10, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07177911 · 32 planned · China
- Sep 15, 2025Early phase 1 study in Lupus Erythematosus, SystemicNCT07193810 · 6 planned · China
Ahead
- Nov 8, 2026Primary completion: early phase 1 study in Lupus Erythematosus, SystemicNCT06888960
- Sep 10, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07177911
- Sep 29, 2027Primary completion: early phase 1 study in Lupus Erythematosus, SystemicNCT07193810
TargetBeta
“A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) CD19, the T-cell surface antigen CD3, and the T-cell specific surface glycoprotein and co-stimulatory molecule CD28, ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07193810Lupus Erythematosus, Systemic · China | Early 1 | Recruiting | Sep 29, 2027 | 6 |
| NCT07177911Lupus Erythematosus, Systemic · China | 1 | Recruiting | Sep 10, 2027 | 32 |
| NCT06888960Lupus Erythematosus, Systemic · China | Early 1 | Recruiting | Nov 8, 2026 | 18 |
| NCT06037018Lymphoma, Non-Hodgkin · China | 1 | Recruiting | Mar 2026 | 44 |
How it is read
Names in the registry
- “CC312”, 4 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 3 studies
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.